John Martin Magenau IV MD
Assistant Professor, Internal Medicine, University of Michigan Medical School
Join to View Full Profile
1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000
Fax+1 734-232-7580
Dr. Magenau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2004 - 2007
Lewis Katz School of Medicine at Temple UniversityClass of 2004
Certifications & Licensure
MI State Medical License 2007 - 2026
IL State Medical License 2004 - 2008
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen Start of enrollment: 2007 Oct 01
- Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Start of enrollment: 2016 Sep 19
Publications & Presentations
PubMed
- A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.Muhammad Umair Mushtaq, John F DiPersio, Jacques Azzi, Brenda W Cooper, Guenther Koehne
Blood. 2026-02-04 - 2 citationsOrca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.Everett Meyer, Amandeep Salhotra, Arpita Gandhi, Jeremy Pantin, Sagar S Patel
Blood. 2025-12-12 - Remission of-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen R...Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly, Manuel Menes, Jacques Azzi
JCO Precision Oncology. 2025-10-01
Abstracts/Posters
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot StudyJohn M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
If I’m Immunocompromised, Should I Keep Wearing My Mask Once I’m Vaccinated?May 28th, 2021
OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRJanuary 27th, 2020
A Phase II Trial of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell TransplantJanuary 21st, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
